Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
| Autor: | Grande, E., Alonso-Gordoa, T., Reig, O., Esteban, E., Castellano, D., Garcia-del-Muro, X., Mendez, M.J., García-Donas, J., González Rodríguez, M., Arranz-Arija, J.A., Lopez-Criado, P., Molina-Cerrillo, J., Mellado, B., Alvarez-Fernandez, C., De Velasco, G., Cuéllar-Rivas, M.A., Rodríguez-Alonso, R.M., Rodríguez-Moreno, J.F., Suarez-Rodriguez, C. |
|---|---|
| Zdroj: | In ESMO Open April 2022 7(2) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|